Agilon Health (AGL) Set to Post Earnings on Wednesday

Key Points

• Agilon Health is expected to report Q3 2026 results after market close on Wednesday, November 4, with analysts forecasting a loss of $1.23 per share and revenue of $1.46 billion.
• The company’s previous quarter exceeded expectations, reporting $1.04 EPS versus the $0.14 consensus estimate and revenue of $1.49 billion, above forecasts of $1.45 billion.
• AGL recently traded at $90.15, while analysts maintain a consensus “Hold” rating and an average price target of $102.25; ratings include six Buys, six Holds and two Sells.

Agilon Health (NYSE:AGL - Get Free Report) is projected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($1.23) per share and revenue of $1.46 billion for the quarter. Investors may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Agilon Health (NYSE:AGL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $1.04 EPS for the quarter, topping the consensus estimate of $0.14 by $0.90. The firm had revenue of $1.49 billion for the quarter, compared to analysts' expectations of $1.45 billion. On average, analysts expect Agilon Health to post ($2.90) EPS for the current fiscal year and $1.20 EPS for the next fiscal year.

Agilon Health Price Performance

NYSE AGL opened at $90.15 on Wednesday. The company has a market cap of $1.51 billion, a PE ratio of -6.32 and a beta of 2.98. The stock's 50 day simple moving average is $88.19 and its 200-day simple moving average is $63.92. Agilon Health has a 1-year low of $7.48 and a 1-year high of $133.04.

Analyst Ratings Changes

Several analysts recently commented on the company. Royal Bank Of Canada set a $125.00 price target on Agilon Health in a research report on Tuesday, September 15th. Citigroup upgraded Agilon Health from a "sell" rating to a "neutral" rating and raised their price objective for the company from $105.00 to $115.00 in a report on Monday, August 10th. Benchmark reaffirmed a "buy" rating and set a $140.00 target price (up from $95.00) on shares of Agilon Health in a research note on Thursday, August 6th. JPMorgan Chase & Co. lifted their target price on shares of Agilon Health from $31.00 to $85.00 and gave the stock an "underweight" rating in a research note on Monday, August 24th. Finally, Wells Fargo & Company reaffirmed an "overweight" rating and set a $146.00 target price (up from $141.00) on shares of Agilon Health in a report on Tuesday, August 11th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $102.25.

About Agilon Health

Agilon Health, Inc is a healthcare company that partners with independent primary care physicians to support the transition from fee-for-service medicine to value-based care. The company works with physician practices serving primarily older adults enrolled in Medicare Advantage and helps them manage the cost, quality and coordination of care for their patient populations.

Agilon provides a technology-enabled platform that includes population health analytics, clinical and administrative support, care coordination resources and practice-management capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.